newsfilter
← Latest News
Business Wire·

AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update

Presented positive data from first five patients in Phase 1/2 cystinosis trial1 showing systemic gene therapy effect at the American Society of Gene and Cell Therapy Annual Meeting; all five patients remain off oral cysteamine Comprehensive Gaucher d